CardieX Limited announced sales results for the first quarter September 2023. In the September quarter the Company has recorded unaudited revenue of $1.36 million (compared to $0.56 million in first quarter of fiscal year 2022), which is a year-on-year growth of 143% across Company's traditional business, with the sales and lease of Company's XCEL and Oscar 2 devices to pharmaceutical companies, research institutions, and specialist clinicians.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.049 AUD | 0.00% | -10.91% | -63.70% |
04-02 | Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes | MT |
04-02 | Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5% | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-63.70% | 9.52M | |
+11.29% | 225B | |
+8.76% | 186B | |
+12.90% | 135B | |
+25.95% | 107B | |
+0.80% | 63.56B | |
+5.62% | 51.32B | |
+11.08% | 51.04B | |
+6.28% | 43.3B | |
+4.80% | 36.99B |
- Stock Market
- Equities
- CDX Stock
- News CardieX Limited
- CardieX Limited Announces Sales Results for the First Quarter September 2023